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Background: Breast cancer is the leading cause of cancer death in females worldwide, and the majority type is
infiltrating ductal carcinoma (IDC). Most of IDC patients died of metastasis and recurrence. Cancer stem cells (CSCs)
are defined with the ability to be self-renewal and potentially promote proliferation and formation of tumors. CSCs
are related to angiogenesis and are important targets in new cancer treatment strategies. In this study, we purposed
to investigate on expression and clinical significances of CSCs marked by CD133 and CD44 in IDC and their relationship
to angiogenesis.
Methods: The specimens of IDC from 325 Chinese patients with follow-up were analyzed for CD133, CD44, CD82, and
CD34 protein expression by immunohistochemical staining. The Pearson chi-square test and t test were used to assess
the associations among the positive staining of these markers and clinicopathological characteristics. Postoperative
overall survival time in these patients with IDC was analyzed by univariate and multivariate analyses.
Results: In IDC tissues, positive rates of 48.6%, 53.8%, and 42.2% were obtained for CD133, CD44, and CD82 protein,
respectively; the mean score of microvessel density (MVD) was 20.5 ± 7.0 in IDC group. And there was a significant
difference between the two groups. There was a positive relationship between the expression of CD133, CD44, and the
score of MVD and the grades of tumor, lymph node metastasis, tumor-node-metastasis (TNM) stages (all P < 0.05);
and the expression of CD82 was negatively related to grades of tumor, lymph node metastasis, and TNM stages
(all P < 0.05). The overall mean survival time of the patients with CD133, CD44, and the score of MVD (≥21) positive
expression was lower than that of patients with negative expression. The overall mean survival time of patients of
CD82-positive expression was longer than that of patients of the negative expression group. The positive expression of
CD133 and CD82, and TNM stages were independent prognostic factors of IDC (P < 0.05).
Conclusions: CSCs, angiogenesis, and aberrant expression of CD82 may be involved in the initiation, development,
metastasis, and recurrence. It is suggested that CSCs, angiogenesis, and CD82 be possible as a therapeutic marker for
anti-tumor therapy.Background
Caner is the leading cause of death in China. Breast can-
cer is the first commonly diagnosed cancer and the first
cause of cancer death in women [1,2] and accounting for
23% of all malignancies [1]. It is well known that the ex-
pression profiles of estrogen receptor (ER), progesterone
receptor (PR), and human epidermal growth factor* Correspondence: chenzhendong@csco.org.cn
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cancer and used for predicting the prognosis and ther-
apy [3]. Over the past 25 years, the breast cancer death
rates have been decreasing in some European and North
American countries [4]. Although rapid progress has re-
cently been made in treatment, such as China, the progno-
sis for patients with breast cancer remains unsatisfactory,
and mortality rate of breast cancer is rising. The main rea-
sons are metastasis, recurrence, and resistance-therapy.is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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predicted the diagnosis and development of breast cancer
[5-7]. The infiltrating breast carcinoma is the first most fre-
quent histological subtype of breast cancer.
Cancer stem cells (CSCs) are defined as a small popu-
lation of tumor cells and termed as self-renewal, prolif-
eration, and therapy resistance and are responsible for
tumor metastasis and tumorigenicity [8-12]. CD133,
which is also known as prominin-1, is a very common
CSC marker and was initially considered as a marker of
hematopoietic stem cells [13]. Later, CD133 was found
expressing in many solid tumors, and it may represent a
putative cancer stem cell marker. Additionally, CD133
has also been found to be a prognostic factor of some
tumors, such as breast, colon, and lung cancer [14-16].
CD44 is a cell-adhesion molecule and is also considered
as a marker of CSC. CD44 is involved in cell to cell
and cell to matrix interactions and signal transduction
[17]. CD44 is a complex family of molecules, which is
encoded by a gene, including 20 exons. The standard
CD44 (CD44s) is consisted of exons 1 to 5 and 15 to
20. Exons 6 to 15 are variable, and variable exons are
commonly identified as v1 to v10, respectively. So,
there are various isoforms of CD44. The role of these
isoforms is not fully clear, although some are believed
that they are necessary to multiple biological functions
of normal cells and also mediate a critical step in some
cancer metastasis [18,19]. CD44 has also been found to
be a poor prognosis in many solid tumors, including
liver, gastric, colon, breast, and lung cancer.
Cancer invasion and metastasis require multiple com-
plex steps and involve a variety of molecules. Angiogen-
esis, which can supply blood and nutrient for cancers
growth, is an important step in cancer invasion and me-
tastasis. Microvessel density (MVD) is a common stand-
ard method of measuring cancer angiogenesis. High
score of MVD in tumors means not only an aggressive
phenotype of tumors but also an easy metastasis of
tumor. And high score of MVD often indicates a poor
prognosis [20,21]. Aberrant expression of suppressor of
metastasis of tumor also plays an important role in can-
cer metastasis. CD82 gene is a suppressor of metastasis
of tumor in many tumors and a member of the tetraspa-
nins superfamily of glycoproteins. It was originally identi-
fied in prostate carcinoma [22]. Down-regulated expression
of CD82 was found in most metastatic cancers [23]. The
latest studies have indicated that aberrant expression of
CD82 could be a useful marker for metastatic and prognos-
tic factor in many tumors. The relationship among CSC,
angiogenesis, and aberrant expression of suppressor of me-
tastasis of tumor in infiltrating ductal carcinoma (IDC) has
not yet been explored. In this research, we performed an
immunohistochemical investigation to explore the role of
the expression of CD133, CD44, CD82, and MVD inclinicopathology and prognosis in 325 specimens of IDC
patients.Methods
Patients and specimens
Paraffin-embedded sections of 325 IDC and their
correspondent adjacent tissues were obtained from the
Department of Pathology, the First Affiliated Hospital
of Bengbu Medical College from January 2004 to December
2008. We excluded patients who received preoperative
chemotherapy or radiotherapy or other anti-tumor therapy.
This research was approved by the ethical committee of
Bengbu Medical College before its start. The age of the pa-
tients ranged from 21 to 74 years, the median age was
45.6 years. There were 91 cases whose tumors diameter
were <2.0 cm, 198 cases that were 2.0 to 4.0 cm, and 36
cases that were ≥4.0 cm. Typing of primary tumors was
performed according to the WHO classification, while the
Ellis and Elston system was used for grading. Seventy-six
cases were at grade 1, 159 cases were at grade 2, and 90
cases were at grade 3. One hundred seventy cases were at
the left breast and 155 cases were at the right breast. A total
of 155 cases had no lymph node metastasis, whereas 170
cases showed lymph node metastasis. According to clin-
ical staging of pathologic tumor-node-metastasis (pTNM),
54 cases were stage I, 123 cases were stage II, 141 cases
were stage III, and 7 cases were stage IV.Immunohistochemical analysis
All samples were fixed with 10% buffered formalin and
embedded in paraffin. Four-micrometer-thick tissue sec-
tions were used for the experiment. All sections were
deparaffinized and dehydrated with xylene and graded
alcohol. Then, the sections were washed in phosphate-
buffered saline (PBS, pH 7.2) for 10 minutes. The en-
dogenous peroxidase activity was quenched by incubation
in methanol containing 3% H2O2 at room temperature for
10 minutes, then heated at 95°C to repair antigens for
30 minutes, and rinsed in PBS several times. The sections
were blocked by goat serum at room temperature for
20 minutes and incubated with mouse monoclonal
CD133 (Abcam, Burlingame, CA, USA), CD44 (LabVi-
sion, Thermo Fisher Scientific, Waltham, MA, USA),
CD34 (LabVision), and CD82 (Santa Cruz, Dallas, TX,
USA) primary antibodies overnight at 4°C in a humidi-
fied chamber. Replacing the primary antibodies with
PBS, performed in the negative control group, the
slides were incubated with a polymer enhancer (re-
agent A) at room temperature for 20 minutes. Washing
with PBS, the slides were incubated with goat anti-mouse
antibody (reagent B) at room temperature for 30 minutes.
After a complete wash by PBS, the slides were develop in
freshly prepared diaminobenzidine (DAB) solution for
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drated, air-dried, and mounted.
Evaluation of score
Slides were reviewed independently by two pathologists
to evaluate the results of immunohistochemical staining
under the light microscope. Ten high power fields were
randomly selected from each slide for scoring expression
of CD133, CD44, and CD82 proteins; both the extent and
intensity of immunohistochemical staining were consid-
ered. The intensity of positivity was scored as follows:
negative was 0, weak was 1, moderate was 2, and strong
was 3. The extent of positivity was scored according to the
percentage of positive staining cells: <10% as 1, 11% to
50% as 2, 51% to 75% as 3, and >75% as 4. The final score
was determined by multiplying the intensity of positivity
and the extent of positivity scores, which yielded a range
score from 0 to 12. Expression of CD133, CD44, and
CD82 was considered positive when the scores were ≥3.
The staining for CD133 and CD44 was mainly confined
to the cell membrane and cytoplasm. The positive staining
for CD82 was mainly confined to the cell membrane and
cytoplasm. The positive staining was presented as brown
granular materials. The positive staining for CD34 was
mainly confined to the cytoplasm and membrane. MVD de-
termined the mean score of small CD34+ vessels counted.
The modified Weidner’s method was used to calculate the
MVD in IDC [24].Figure 1 Expressions of CD133, CD44, and CD82 proteins. (A) Expressi
expressed as positive in the membrane and cytoplasm of cancer cells (inte
final score = 12, CD133 × 400, G 2). (B) Expression of CD44 protein in IDC. C
cancer cells (intensity of positivity: strong = 3, percentage of positive cells: >
protein in IDC. CD82 was expressed as positive in the membrane and cyto
of positive cells: >75% = 4, final score = 8, CD82 × 400, G 2).Statistical analysis
Fisher’s exact test, Pearson chi-square test for trends in
proportions, t test analysis, Spearman’s correlate ana-
lysis, and Kaplan-Meier’s method with log rank test or
Cox regression method for univariate or multivariate
overall survival analysis were used to assess the associa-
tions among the positive staining of CD133 or CD44 or
CD82 or MVD and clinicopathological indices by SPSS
17.0 software for windows (Chicago, IL, USA). A value
of P < 0.05 was considered statistically significant.
Results
The relationship between expression of CD133, CD44,
CD82, and MVD and clinicopathological factors
The positive expression of CD133 and CD44 protein
was 48.6% (158/325) and 53.8% (175/150) in the IDC
and 9.2% (30/325) and 1.5% (5/325) in the control
group, respectively. There was a significant difference
between the IDC group and the control group (P < 0.001)
(Figure 1A, B). And there was a significant difference be-
tween the expression of CD133 and CD44 protein and
grade of tumors, lymph node metastasis, and pTNM stage
(P < 0.05). The positive expression of CD82 was 42.2%
(137/325) in the IDC group and 98.5% (320/325) in the
control group (Figure 1C). There was a significant dif-
ference between the IDC group and the control group
(P < 0.001). And there was a negative relationship be-
tween the expression of CD82 protein expression and theon of CD133 protein in infiltrating ductal carcinoma. CD133 was
nsity of positivity: strong = 3, percentage of positive cells: >75% = 4,
D44 was expressed as positive in the membrane and cytoplasm of
75% = 4, final score = 12, CD44 × 400, G 2). (C) Expression of CD82
plasm of cancer cells (intensity of positivity: moderately = 2, percentage
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(P < 0.05) (Table 1). The score of MVD of IDC was 20.5 ±
7.0, and the MVD score was found to be closely linked to
grade of tumors, lymph node metastasis, and pTNM stage
(P < 0.05) (Table 1). However, the positive expression of
CD133, CD44, and CD82 and the score of MVD had no
significant relationship with age, diameter of tumor, and
site of tumor (P > 0.05) (Table 1).
Prognosis and multivariate analysis
Follow-up data showed that there was a significantly de-
creasing trend in the overall mean survival time between
the carcinomas with the positive expression of CD133 pro-
tein (46.8 months) and those negative expression of CD133
(57.9 months) (log rank = 16.243, P < 0.001, Figure 2A).
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Positive 57 73 50 80was significantly less than that of the negative expression
group (log rank = 5.340, P = 0.021, Figure 2B). The survival
time of the score of MVD <21 group was significantly
longer than that of the score ≥21 group (log rank =
9.623, P = 0.002, Figure 2C). The survival time of the
CD82-positive expression group was significantly lon-
ger than that of the negative expression group (log
rank = 23.644, P < 0.001, Figure 2D). A multivariate
analysis revealed that the expression of CD133, CD82,
and PR and pTNM stage was independent prognosis
factors for overall survival time of IDC (Table 2).
Correlation of CD133, CD44, CD82, and the score of MVD
in IDC
In the positive expression of CD133 group, the mean
score of MVD was 22.1 ± 6.3; in the negative expressionD and clinicopathological characteristics in IDC
value
CD82
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Figure 2 Kaplan-Meier survival analysis by CD133, CD44, MVD, and CD82 statuses. (A) Kaplan-Meier survival analysis by CD133 status (n= 325).
Mean overall survival (OS) time was 46.8 months for the CD133-positive group and 57.9 months for the CD133-negative group (log rank = 16.243, P< 0.001).
(B) Kaplan-Meier survival analysis by CD44 status (n= 325). Mean OS time was 48.7 months for the CD44-positive group and 57.0 months for the
CD44-negative group (log rank = 5.340, P = 0.021). (C) Kaplan-Meier survival analysis by MVD status (n = 325). Mean OS time was 48.4 months
for the MVD ≥21 group and 57.0 months for the MVD <21 group (log rank = 9.623, P = 0.002). (D) Kaplan-Meier survival analysis by CD82 status
(n = 325). Mean OS time was 60.8 months for the CD82-positive group and 46.5 months for the CD82-negative group (log rank = 23.644, P < 0.001).
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There was a positive association between CD133 expres-
sion and the score of MVD (r = 0.270, P < 0.001) and the
same association between CD44 expression and CD133
expression (r = 0.123, P = 0.027). There was a negative
association between CD82 expression and CD133 expres-
sion (r = −0.120, P = 0.031) or CD44 expression (r = −0.372,P < 0.001) or the score of MVD (r = −0.194, P < 0.001) or
Her-2 expression (r = −0.137, P = 0.013) (Table 3).
Discussion
It has been well accepted that CSC plays an important
role in tumorigenesis and tumor development. The small
population of CSC has been found in many solid tumors
Table 2 Multivariate survival analysis of 325 patients
with IDC
Covariable B SE P RR 95% CI
CD133 0.328 0.135 0.015 1.388 1.065 to 1.809
CD82 −0.484 0.147 0.001 0.617 0.462 to 0.823
PR −0.376 0.149 0.011 0.687 0.513 to 0.919
pTNM 0.290 0.146 0.047 1.336 1.004 to 1.777
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clinical prognosis [25-27]. The aim of this study was to
investigate the expression of the CSC markers CD133,
CD44, and CD82 and the score of MVD in IDC and find
suitable molecular targets for therapy and predict the
prognosis of IDC patients.
CD133 is the most common marker of CSC and has
been used as a marker to identify CSC in many solid tu-
mors. In this research, we used immunohistochemical
staining to detect the CD133 protein expression in 158
(48.6%), and it was significantly related to the poor prog-
nosis of IDC patients. Further study showed that CD133
protein expression was correlated with grade of tumor,
TNM stage, and lymph node metastasis. In addition, we
documented a poor survival time with positivity of
CD133 protein expression. This research was consistent
with previous researches [16,28,29]. However, there was
often a controversy whether CD133 was a marker of
CSC or not. Some studies [16,30,31] had showed that
the expression of CD133 was not only in CSC but also
in normal tissues. Some studies thought that CD133
might play a critical role in tumorigenesis [16,30]. Al-
though this study showed that the expression of CD133
was broadly distributed in IDC cells, only a minor part
of cells which CD133 was positive expression possess
the capacity of stem cells [16,32]. And these cells after
routine chemotherapy or radiotherapy may lead to tumor
recurrence and metastasis [33].
CD44 has also been used as a marker of CSC. CD44-
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Positive 80 57 93 44proliferating and forming clones than CD44 negative
tumor cells [34]. In this study, we found the association
of increased CD44 protein expression with aggressive
tumor-related features, including advanced stage, grade,
and lymph node metastasis. We also found a worse sur-
vival time with positive expression of CD44 protein in
univariate, but not multivariable survival time analysis.
This result was consistent with previous studies in other
tumor types [35,36].
MVD is the most common standard of measuring
tumor angiogenesis and is closely linked to tumor growth
and prognostic of patients. MVD may represent the differ-
entiation and vascular network parameters in tumors [35].
In our research, we confirm the relationship between the
increased score of MVD with advanced stage, grade, and
lymph node metastasis and a shorter survival time. A
similar result was found in other studies [16,37].
CD82 is a gene which is located on human chromo-
some 11p11.2 and plays a critical role in cell adhesion,
migration, signaling, and invasion [38,39]. In our re-
search, we found that CD82 protein expression was
negatively linked to the advanced stage, grade, and
lymph node metastasis. Further survival analysis showed
that the patients with CD82-positive expression had a
significantly longer survival time than that of CD82-
negative expression. Loss-expression or down-expression of
CD82 promotes tumor cell invasion and metastasis. CD82
can inhibit tyrosine phosphorylation of β-catenin and
stabilize E-cadherin-β-catenin complexes and, thus, prevent
tumor cell dissemination from primary tumors [40,41].
Furthermore, CD82 expression was negatively associ-
ated with CD133 and CD44 expression and MVD. And
there was a positive relationship between CD133 expres-
sion or CD44 expression or MVD. Only a small part of
tumor cells which expressed CD133 protein possessed
the capacity of CSC. The niche where CSC resides can
regulate CSC self-renewal, so vascular niche or neovas-
cularization can regulate CSC fate [16]. CSC can pro-
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tumor cells can stimulate angiogenesis in order to get
adequate blood and nutrition. CSC may contribute to
the formation of neovascularization [21]. CSC can meet
their need to manipulate stromal cells by inducing a pre-
metastatic niche in distant organs for their arrival [42].
Loss-expression or down-expression of CD82 can fur-
ther promote the metastatic ability of tumor cells.
Conclusions
It is suggested that CSC may play a critical role in the
evolution of IDC. The combined detection of CD133,
CD44, CD82, and MVD, to some extent, may reflect the
biological behavior and be considered as potential
markers for the prognosis of IDC, thus give the choice
of molecular target therapy.
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